At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 806 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Pregabalin 660mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jan 5, 2011·Updated Jan 28, 2021
In Brief
A Phase 3 clinical trial evaluating Pregabalin and placebo for Post Herpetic Neuralgia. Completed, enrolled 806 participants across 146 sites in 17 countries.
Detailed Summary
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Herpetic Neuralgia
CountriesBulgaria, Colombia, Croatia, Czechia, Denmark, Germany, Hong Kong, India, Poland, Russia, Serbia, Slovakia, South Africa, Sweden, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartMar 2011
Primary CompletionSep 2014
Study CompletionNov 2014
TodayJul 2026
First PostedJan 5, 2011
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 15.5 years ago
Interventions
Pregabalindrug
Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
placebodrug
Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks